University of California other research news
UCSF researchers and colleagues at Children's Hospital (Boston, Mass.) and Lexigen Pharmaceuticals Corp. (Lexington, Mass.) published in Science an analysis of anti-angiogenic factors in a transgenic mouse model of pancreatic cancer. They found that British Biotech Group plc's BB-94 batimastat (which the company has dropped), EntreMed Inc.'s endostatin and the combination of endostatin plus angiostatin were most effective in preventing tumor formation. Takeda Chemical Industries Ltd.'s AGM-1470 (TNP470) and the combination of endostatin plus angiostatin were most effective in causing tumor regression, and all were effective in preventing growth of small tumors. The researchers noted that anti-angiogenic drugs may be most efficacious when targeted to specific stages of cancer. ...